BL
Therapeutic Areas
Idorsia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| QUVIVIQ (daridorexant) | Insomnia | Approved/Commercial |
| TRYVIO/JERAYGO (aprocitentan) | Resistant Hypertension | Approved/Commercial |
| Cenerimod | Systemic Lupus Erythematosus (SLE) | Phase 3 |
| Selatogrel | Acute Myocardial Infarction (AMI) | Phase 3 |
| Daridorexant (for PTSD) | Post-Traumatic Stress Disorder | Clinical Study |
Leadership Team at Idorsia
JC
Jean-Paul Clozel
Chairman of the Board and Interim CEO
AG
Arno Groenewoud
Executive Vice President, Chief Financial Officer
MC
Martine Clozel
Executive Vice President, Chief Scientific Officer & Head of Research
JG
Julien Gander
Chief Legal & Corporate Development Officer
AG
Alberto Gimona
Executive Committee Member